Women’s health biotech Freya Biosciences advances microbial therapy for IVF implantation failure

Freya Biosciences announces positive Phase 1 first-in-human data with FB301 for IVF-related embryo implantation failure

FB301 was safe and well tolerated in healthy female subjects, with all primary and secondary endpoints met Clinically meaningful microbiome modulation observed, including significant improvement up to 6-month follow-up Results support progression into Phase 2, with FDA IND clearance granted in the US and CTA approved in Germany Copenhagen, Denmark and Boston, Massachusetts, 16 April […] The post Freya Biosciences announces positive Phase 1 first…

Women’s health biotech Freya Biosciences advances microbial therapy for IVF implantation failure

Freya Biosciences is moving a microbial immunotherapy for IVF implantation failure into mid-stage trials after promising results in healthy volunteers. The Phase 2 study is testing Freya’s candidate, called FB301, in women with vaginal dysbiosis ...